Epidemiology Data Slicer
Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and PCSK9…
Clarivate Epidemiology's coverage of dyslipidemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dyslipidemia for each…
Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current lipid-modifying therapies include statins, ezetimibe, fibrates, omega-3 fatty acid compounds…
Dyslipidemia is an important modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), a leading causes of death globally. Statins continue to dominate treatment for dyslipidemia,…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key dyslipidemia patient populations covering 171 countries and more…
Dyslipidemia is a key modifiable risk factor for cardiovascular disease (CVD), which is primarily managed by statin therapy. With positive CV outcomes data for certain nonstatin therapies including…
Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current lipid-modifying therapies include statins, ezetimibe, fibrates, omega-3 fatty acid compounds…
MARKET OUTLOOK Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds…
MARKET OUTLOOK Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds…
Hypertriglyceridemia refers to abnormalities in the concentration of triglycerides in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease and, with very high levels…
Hypertriglyceridemia is characterized by elevated triglyceride (TG) levels. In addition to lifestyle changes, current treatment focuses on improving patients’ TG levels with the aim to reduce the…
Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and PCSK9…
Dyslipidemia is an important modifiable risk factor for cardiovascular disease, which is one of the leading causes of death globally. Statins continue to dominate treatment of dyslipidemia, driven…
MARKET OUTLOOK Dyslipidemia is an important modifiable risk factor for CV disease and is primarily managed with statin therapy. Based on the positive CVOT data for certain nonstatin therapies,…